161 related articles for article (PubMed ID: 32687165)
21. Generation of a TP53-modified porcine cancer model by CRISPR/Cas9-mediated gene modification in porcine zygotes via electroporation.
Tanihara F; Hirata M; Nguyen NT; Le QA; Hirano T; Takemoto T; Nakai M; Fuchimoto DI; Otoi T
PLoS One; 2018; 13(10):e0206360. PubMed ID: 30352075
[TBL] [Abstract][Full Text] [Related]
22. Concurrent live imaging of DNA double-strand break repair and cell-cycle progression by CRISPR/Cas9-mediated knock-in of a tricistronic vector.
Otsuka K; Tomita M
Sci Rep; 2018 Nov; 8(1):17309. PubMed ID: 30470841
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide CRISPR/Cas9 screening for therapeutic targets in NSCLC carrying wild-type TP53 and receptor tyrosine kinase genes.
Wang Q; Li J; Zhu J; Mao J; Duan C; Liang X; Zhu L; Zhu M; Zhang Z; Lin F; Guo R
Clin Transl Med; 2022 Jun; 12(6):e882. PubMed ID: 35692096
[TBL] [Abstract][Full Text] [Related]
24. Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.
Offin M; Chan JM; Tenet M; Rizvi HA; Shen R; Riely GJ; Rekhtman N; Daneshbod Y; Quintanal-Villalonga A; Penson A; Hellmann MD; Arcila ME; Ladanyi M; Pe'er D; Kris MG; Rudin CM; Yu HA
J Thorac Oncol; 2019 Oct; 14(10):1784-1793. PubMed ID: 31228622
[TBL] [Abstract][Full Text] [Related]
25. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
[TBL] [Abstract][Full Text] [Related]
26. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
27. Ectopic expression of RAD52 and dn53BP1 improves homology-directed repair during CRISPR-Cas9 genome editing.
Paulsen BS; Mandal PK; Frock RL; Boyraz B; Yadav R; Upadhyayula S; Gutierrez-Martinez P; Ebina W; Fasth A; Kirchhausen T; Talkowski ME; Agarwal S; Alt FW; Rossi DJ
Nat Biomed Eng; 2017 Nov; 1(11):878-888. PubMed ID: 31015609
[TBL] [Abstract][Full Text] [Related]
28. Functional interrogation of DNA damage response variants with base editing screens.
Cuella-Martin R; Hayward SB; Fan X; Chen X; Huang JW; Taglialatela A; Leuzzi G; Zhao J; Rabadan R; Lu C; Shen Y; Ciccia A
Cell; 2021 Feb; 184(4):1081-1097.e19. PubMed ID: 33606978
[TBL] [Abstract][Full Text] [Related]
29.
Marshall AE; Roes MV; Passos DT; DeWeerd MC; Chaikovsky AC; Sage J; Howlett CJ; Dick FA
Mol Cell Biol; 2019 Aug; 39(16):. PubMed ID: 31138663
[TBL] [Abstract][Full Text] [Related]
30. The protocol of tagging endogenous proteins with fluorescent tags using CRISPR-Cas9 genome editing.
Wu ZS; Gao Y; Du YT; Dang S; He KM
Yi Chuan; 2023 Feb; 45(2):165-175. PubMed ID: 36927663
[TBL] [Abstract][Full Text] [Related]
31. Assaying Cell Cycle Progression via Flow Cytometry in CRISPR/Cas9-Treated Cells.
Geisinger JM; Stearns T
Methods Mol Biol; 2021; 2329():195-204. PubMed ID: 34085224
[TBL] [Abstract][Full Text] [Related]
32. Profiling Genome-Wide Specificity of CRISPR-Cas9 Using Digenome-Seq.
Kim D; Kim JS
Methods Mol Biol; 2021; 2162():233-242. PubMed ID: 32926386
[TBL] [Abstract][Full Text] [Related]
33. No apparent p53 activation in CRISPR-engineered gene-edited rabbits.
Zhang T; Li J; Wang T; Zhao F; Sui T
J Cell Mol Med; 2021 Nov; 25(21):10313-10317. PubMed ID: 34609046
[TBL] [Abstract][Full Text] [Related]
34. Optical Control of a CRISPR/Cas9 System for Gene Editing by Using Photolabile crRNA.
Zhang Y; Ling X; Su X; Zhang S; Wang J; Zhang P; Feng W; Zhu YY; Liu T; Tang X
Angew Chem Int Ed Engl; 2020 Nov; 59(47):20895-20899. PubMed ID: 33448579
[TBL] [Abstract][Full Text] [Related]
35. Roles of TP53 gene in the development of resistance to PI3K inhibitor resistances in CRISPR-Cas9-edited lung adenocarcinoma cells.
Hou J; Cao X; Cheng Y; Wang X
Cell Biol Toxicol; 2020 Oct; 36(5):481-492. PubMed ID: 32239370
[TBL] [Abstract][Full Text] [Related]
36. Establishment of TP53-knockout canine cells using optimized CRIPSR/Cas9 vector system for canine cancer research.
Eun K; Park MG; Jeong YW; Jeong YI; Hyun SH; Hwang WS; Kim SH; Kim H
BMC Biotechnol; 2019 Jan; 19(1):1. PubMed ID: 30606176
[TBL] [Abstract][Full Text] [Related]
37. CRISPR/Cas9-Induced DNA Damage Enriches for Mutations in a p53-Linked Interactome: Implications for CRISPR-Based Therapies.
Jiang L; Ingelshed K; Shen Y; Boddul SV; Iyer VS; Kasza Z; Sedimbi S; Lane DP; Wermeling F
Cancer Res; 2022 Jan; 82(1):36-45. PubMed ID: 34750099
[TBL] [Abstract][Full Text] [Related]
38. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
Soriano V
AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
[TBL] [Abstract][Full Text] [Related]
39. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD; Corella A; Coleman I; De Sarkar N; Kaipainen A; Ha G; Gulati R; Ang L; Chatterjee P; Lucas J; Pritchard C; Risbridger G; Isaacs J; Montgomery B; Morrissey C; Corey E; Nelson PS
Cell Rep; 2020 May; 31(8):107669. PubMed ID: 32460015
[TBL] [Abstract][Full Text] [Related]
40. Cell-specific CRISPR-Cas9 activation by microRNA-dependent expression of anti-CRISPR proteins.
Hoffmann MD; Aschenbrenner S; Grosse S; Rapti K; Domenger C; Fakhiri J; Mastel M; Börner K; Eils R; Grimm D; Niopek D
Nucleic Acids Res; 2019 Jul; 47(13):e75. PubMed ID: 30982889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
